Access to prescribing information for paediatric medicines in the USA: Post-modernization

British Journal of Clinical Pharmacology

Volumn 67, Issue 3, 2009, Pages 341-346

  Young, Larissa ^b   Lawes, Francis ^b   Tordoff, June ^b   Norris, Pauline ^b   Reith, David ^a,c  

^a DUNEDIN HOSPITAL   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Formulations; Information; Medicines; Off label; Paediatric; Unlicensed

Indexed keywords

GENERIC DRUG;

ADOLESCENT; ADULT; AGE; ARTICLE; CHILD; DRUG FORMULATION; DRUG IDENTIFICATION; DRUG INFORMATION; HUMAN; INFANT; INFORMATION SERVICE; NEWBORN; PEDIATRICS; PHYSICIAN DESK REFERENCE; PRESCHOOL CHILD; PRESCRIPTION; PRIORITY JOURNAL; UNITED STATES;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG INFORMATION SERVICES; HUMANS; INFANT; INFANT, NEWBORN; LEGISLATION, DRUG; LICENSURE; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; REFERENCE BOOKS; UNITED STATES;

EID: 62949107279     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03356.x     Document Type: Article

References (24)

1. Food and Drug Administration. Best Pharmaceuticals for Children Act. Available at http://www.fda.gov/opacom/laws/pharmkids/contents.html (last accessed 1 September 2007).
2. Food and Drug Administration. Pediatric Research Equity Act. Available at http://www.fda.gov/cder/pediatric/S-650-PREA.pdf (last accessed 1 September 2007).
3. American Academy of Pediatrics. Improvements made in the 2007 Reauthorization of The Best Pharmaceuticals for Children Act (BPCA) and The Pediatric Research Equity Act (PREA). Available at http://www.aap.org/advocacy/ washing/Therapeutics/docs/bpcapreaonepage.pdf (last accessed 15 April 2008).
4. European Medicines Agency. The EU Paediatric Regulation, 2007. Available at http://www.emea.europa.eu/htms/human/paediatrics/regulation.htm (last accessed 15 April 2008).
5. Balakrishnan K, Grieve J, Tordoff J, Norris P, Reith D. Pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002. J Clin Pharmacol 2006 46 : 1038 43.
6. Benjamin DKJ, Smith PB, Murphy MD, Roberts R, Mathis L, Avant D, Califf RM, Li JS. Peer-reviewed publication of clinical trials completed for pediatric exclusivity. JAMA 2006 296 : 1266 73.
7. Grieve J, Tordoff J, Reith D, Norris P. Effect of the Pediatric Exclusivity Provision on children's access to medicines. Br J Clin Pharmacol 2005 59 : 730 5.
8. Li JS, Eisenstein EL, Grabowski HG, Reid ED, Mangum B, Schulman KA, Goldsmith JV, Murphy MD, Califf RM, Benjamin DKJ. Economic return of clinical trials performed under the pediatric exclusivity program. JAMA 2007 297 : 480 8.
9. Balakrishnan K, Tordoff J, Norris P, Reith D. Establishing a baseline for the monitoring of medicines availability for children in the UK: 1998 to 2002. Br J Clin Pharmacol 2007 63 : 85 91.
10. Chui J, Tordoff J, Kennedy J, Reith D. Trends in accessibility to medicines for children in New Zealand: 1998-2002. Br J Clin Pharmacol 2004 57 : 322 7.
11. Chui J, Tordoff J, Reith D. Changes in availability of paediatric medicines in Australia between 1998 and 2002. Br J Clin Pharmacol 2005 59 : 736 42.
12. Nahata MC. Pediatric drug formulations: challenges and potential solutions. Ann Pharmacother 1999 33 : 247 9.
13. American Academy of Pediatrics. Side-by-side comparison of 2007 reauthorization and prior law. Available at http://www.aap.org/advocacy/washing/ Therapeutics/docs/bpcareasidexside.pdf (last accessed 15 April 2008).
14. Arky R. Physicians' Desk Reference, 52th edn. Montvale, NJ : Medical Economics Company, 1998.
15. Walsh P. Physicians' Desk Reference, 56th edn. Montvale, NJ : Medical Economics Company, 2002.
16. Thomson PDR. Physician's Desk Reference Electronic Library 2006 CD-ROM], Version 7.0.306a, 2007.
17. Mehta DK, ed. British National Formulary, 42nd edn. London : British Medical Association, 2001.
18. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Clinical Investigation of Medicinal Products in the Pediatric Population, 2000.
19. WHO Collaborating Centre for Drug Statistics Methodology. ATC Index 2008. Available at http://www.whocc.no/atcddd (last accessed 15 April 2008).
20. Heracleous L, Murray J. The urge to merge in the pharmaceutical industry. European Management Journal 2001 19 : 430 7.
21. Food and Drug Administration. Vioxx (rofecoxib) Questions and Answers. Available at http://www.fda.gov/Cder/drug/infopage/vioxx/vioxxQA.htm (last accessed 30 September 2007).
22. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, Polyp A. Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005 352 : 1092 102.
23. Merck. Merck announces voluntary worldwide withdrawal of VIOXX®. http://www.vioxx.com/vioxx/documents/english/vioxx-press-release.pdf (last accessed 30 September 2007).
24. US Food and Drug Administration Center for Drug Evaluation and Reasearch. Pediatric Exclusivity Labeling, 30 September 2007.